Liminatus Pharma (NASDAQ:LIMN) received a delisting notice from Nasdaq on Tuesday. The company failed to meet the $50 million market value of listed securities and $15 million market value of publicly held shares requirement by May 18, 2026.
With a current market cap of just $10.91 million, the stock has plunged 95.5% over the past year, trading at $0.25. Bond.az data shows the company is burning cash quickly, with negative free cash flow of $9.98 million.
Unless Liminatus appeals to the Nasdaq Hearings Panel by May 27, 2026, trading will be suspended on May 29, 2026. The company intends to appeal.












